Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ra-223 dichloride Clear all
Completed Phase 2 Interventional Results available

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

NCT03304418
View directory record Official record
Conditions
Prostate Cancer Metastatic to Bone
Interventions
Radium Ra 223 Dichloride, Radiation
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

NCT02278055
View directory record Official record
Conditions
Metastatic Prostate Cancer, Pain
Interventions
Radium-223
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

NCT03996473
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

NCT02366130
View directory record Official record
Conditions
Breast Cancer
Interventions
Ra-223 dichloride, Denosumab, Hormone Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02582749
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

NCT04516161
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational

Multi-academic Center Study of Xofigo Patients

NCT03419442
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant
Interventions
Xofigo, Taxotere, Jevtana
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 26, 2026, 1:49 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

NCT02605356
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

NCT02899104
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Xofigo (Radium-223 dichloride, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

NCT05133440
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium dichloride, PET Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Not applicable Interventional Results available

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

NCT02135484
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alpharadin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

NCT02034552
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone, Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 26, 2026, 1:49 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

NCT04109729
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Nivolumab, Radium-223
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

NCT04090398
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Paclitaxel, Radium Ra 223 Dichloride, Single Photon Emission Computed Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

NCT02518698
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years to 88 Years · Male only
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 26, 2026, 1:49 AM EDT
Completed No phase listed Observational Results available

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT02141438
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
49
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Daly City, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 26, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Radium-223 Dichloride Long-term Follow-up Program

NCT02312960
View directory record Official record
Conditions
Neoplasm Metastasis / Bone and Bones
Interventions
Data Collection
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
15
States / cities
Anchorage, Alaska • Tucson, Arizona • Plantation, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 26, 2026, 1:49 AM EDT
Suspended Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 1:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

NCT03317392
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Radium Ra 223 Dichloride
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 26, 2026, 1:49 AM EDT